Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALVRNYSE:JATTNYSE:NKGNNASDAQ:RUBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALVRAlloVir$2.60+4.4%$3.96$7.96▼$24.15$13.11M0.6316,830 shs28,792 shsJATTJATT Acquisition$1.18-2.5%$1.21$7.80▼$12.38$20.36MN/A41,322 shs171,748 shsNKGNNKGen Biotech$0.24+7.2%$0.25$0.10▼$1.37$10.79M1.21.57 million shs39,687 shsRUBYRubius Therapeutics$0.06$0.04$0.00▼$0.38$5.16M2.591.15 million shs755,858 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALVRAlloVir+4.42%+1.17%-6.81%-71.14%-85.11%JATTJATT Acquisition-2.48%+6.31%+15.69%-12.92%-65.09%NKGNNKGen Biotech+2.75%-10.40%-21.40%+37.17%-82.77%RUBYRubius Therapeutics0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALVRAlloVirN/AN/AN/AN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ANKGNNKGen Biotech0.3632 of 5 stars0.03.00.00.00.62.50.0RUBYRubius TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALVRAlloVir 0.00N/AN/AN/AJATTJATT Acquisition 0.00N/AN/AN/ANKGNNKGen Biotech 0.00N/AN/AN/ARUBYRubius Therapeutics 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/AJATTJATT AcquisitionN/AN/A$0.04 per share27.08($0.53) per shareN/ANKGNNKGen Biotech$80K134.90N/AN/A($2.68) per share-0.09RUBYRubius TherapeuticsN/AN/AN/AN/A$0.17 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALVRAlloVir-$190.42M-$20.23N/A∞N/AN/A-71.03%-61.27%8/7/2025 (Estimated)JATTJATT Acquisition$6.85MN/A0.00∞N/AN/A-49.58%2.84%N/ANKGNNKGen Biotech-$82.94M-$2.45N/A∞N/AN/AN/A-479.36%N/ARUBYRubius Therapeutics-$179.67MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALVRAlloVirN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/ANKGNNKGen BiotechN/AN/AN/AN/AN/ARUBYRubius TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALVRAlloVirN/A86.7886.78JATTJATT AcquisitionN/A0.150.15NKGNNKGen BiotechN/A0.020.02RUBYRubius TherapeuticsN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALVRAlloVir66.05%JATTJATT Acquisition47.97%NKGNNKGen Biotech76.17%RUBYRubius TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipALVRAlloVir32.07%JATTJATT Acquisition20.00%NKGNNKGen Biotech10.36%RUBYRubius Therapeutics5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALVRAlloVir1105.04 million3.43 millionOptionableJATTJATT Acquisition317.25 million13.80 millionNot OptionableNKGNNKGen BiotechN/A44.95 million40.29 millionNot OptionableRUBYRubius Therapeutics690.48 million85.69 millionNot OptionableRUBY, JATT, ALVR, and NKGN HeadlinesRecent News About These CompaniesHere’s how to get the El Rubius skin in Fortnite with the most adorable back blingSeptember 17, 2024 | oneesports.ggOAll About the Rubius Skin in FortniteSeptember 17, 2024 | esports.netETwitch star Rubius is giving Fortnite players a good reason to buy his skinSeptember 17, 2024 | dexerto.comDFortnite Fans Only Want One Thing from the Rubius SkinSeptember 17, 2024 | msn.comHow to get the Rubius Icon Series skin in FortniteSeptember 16, 2024 | dexerto.comDHow to Get the Exclusive Rubius Fortnite DropSeptember 15, 2024 | msn.comRubius teases potential Fortnite Icon Series skin in cryptic YouTube videoAugust 4, 2024 | dexerto.comD‘Expats’ Star Ruby Ruiz to Lead James J. Robinson’s Directorial Debut ‘First Light’ (EXCLUSIVE)April 26, 2024 | yahoo.comVacant Rubius property generating interest after 1 year on marketApril 18, 2024 | pbn.comPSensorium Therapeutics Appoints Sam Rasty as Chief Business OfficerApril 17, 2024 | citizentribune.comCVacant RI biotech space, once owned by Rubius Therapeutics, offered at 'deeply discounted price'March 11, 2024 | bizjournals.comRubius Therapeutics Inc RUBYNovember 5, 2023 | morningstar.comM‘Like playing the lottery’: Laid-off life sciences workers give a snapshot of a cooling-down sectorOctober 16, 2023 | bostonglobe.comBRuby Dunne Biography & MoviesSeptember 22, 2023 | tribute.caTParenting Vlogger Ruby Franke Held Without Bail on Child Abuse ChargesSeptember 14, 2023 | oxygen.comOYouTuber mom Ruby Franke arrested and charged in child abuse investigation: What to knowSeptember 8, 2023 | today.comTRuby GonzalesAugust 21, 2023 | dailynews.comDRUBY - Rubius Therapeutics, Inc.August 2, 2023 | uk.finance.yahoo.comNorth American Morning Briefing: Alphabet, -2-July 25, 2023 | morningstar.comMRuby Rivera, 23ABCJune 30, 2023 | turnto23.comTNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRUBY, JATT, ALVR, and NKGN Company DescriptionsAlloVir NASDAQ:ALVR$2.60 +0.11 (+4.42%) As of 06/25/2025AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.JATT Acquisition NYSE:JATT$1.18 -0.03 (-2.48%) As of 06/25/2025JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.NKGen Biotech NYSE:NKGN$0.24 +0.02 (+7.19%) As of 11:17 AM EasternNKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.Rubius Therapeutics NASDAQ:RUBYRubius Therapeutics, Inc., a biopharmaceutical company, focuses on the development of red cell therapeutics for the treatment of cancer and autoimmune diseases. The company was formerly known as VL26, Inc and as changed its name to Rubius Therapeutics, Inc. in 2015. Rubius Therapeutics, Inc. was incorporated in 2013 and is based in Foxborough, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Skyworks Stock Down 16% in 2025, Poised for AI Edge Surge Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Tesla: The Next Month Could Make or Break the Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
